Skip To Main Content
Zaoyu Wang on Muck Rack

Zaoyu Wang

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Zaoyu

Contact Zaoyu, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Tislelizumab plus lenvatinib in advanced fumarate hydratase-deficient renal cell carcinoma: a single-arm, phase 2 trial with metabolic biomarker analysis

|
By Wen Kong, Yunze Xu, Guiqin Liu, Wenwen Lv, Zaoyu Wang, Dengfeng Cao, Feng Jiao, Jiong Hu, Xiaoyu Wu, Jiwei Huang, Yonghui Chen, Wei Zhai, Xiaorong Wu, Jiahua Pan, Yiran Huang, Guangyu Wu, Liang Zheng, Wei Xue, Jin Zhang
| Nature Verified
Abstract Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a rare, aggressive kidney cancer with no established standard of care. This phase 2 trial (NCT05877820) assessed first-line tislelizumab plus lenvatinib in advanced FH-RCC (N = 20). The primary endpoint was objective response rate (ORR); secondary endpoints included progression-free survival (PFS), overall survival (OS), disease control rate (DCR), duration of response (DOR) and safety.
Open in Who Shared Issue with article?

Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial

|
By Jiwei Huang, Yueming Wang, Fan Xu, Zaoyu Wang
| bmj.com
Discussion Our trial showed that axitinib plus toripalimab can be used in a presurgery setting of locally advanced RCC. We observed promising antitumor activity of this combination with acceptable toxicity. Most patients showed primary tumor and TT shrinkage. The overall toxicity was comparable between this trial and the previous trial involving an axitinib-ICI combination in a presurgery setting.21 A part of non-metastatic RCC was high risk for recurrence after nephrectomy.
Open in Who Shared Issue with article?
See all 2 articles